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A B S T R A C T   
Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases 
the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year- 
old patient admitted to the ICU with severe respiratory distress caused by COVID-19 pneumonia who developed 
pulmonary aspergillosis. On the basis of these findings, we suggest early testing for pulmonary aspergillosis in 
COVID-19 patients treated with tocilizumab.   
1. Introduction 
Aspergillus is an opportunistic fungus mainly affecting immunocom-
promised patients. A high rate of invasive pulmonary aspergillosis has 
been demonstrated among critically ill patients admitted to the ICU with 
severe influenza, which may contribute to their high odds of mortality 
[1]. In the early days of the Sars-CoV-2 pandemic, several case reports 
emerged from Wuhan of COVID-19-associated pulmonary aspergillosis 
(CAPA) [2]. Many risk factors for CAPA were recognized among criti-
cally ill COVID-19 patients, including lymphopenia, high levels of sys-
temic pro-inflammatory cytokines, and the use of steroids [3]. 
Tocilizumab is a recombinant humanized monoclonal antibody 
against the interleukin-6 receptor. Initially, it showed promising results 
in reducing the severity of COVID-19 infection in critically ill patients. It 
dramatically reduces the potent inflammatory effects of IL-6 responsible 
for causing the lung damage and eventual multiorgan failure associated 
with COVID-19 [4]. A large retrospective study found that tocilizumab 
reduced the risk of death and the odds of needing mechanical ventilation 
in severe COVID-19 pneumonia [5]. However, subsequent findings from 
large randomized controlled trials raised doubts regarding these 
findings. 
Here, we report the case of a critically ill patient who developed 
CAPA following tocilizumab administration. 
2. Case 
A 69-year-old man was admitted to the emergency department (ED) 
with fever and a cough which he had had for two days. His medical 
history included HBV-related liver cirrhosis, arterial hypertension and 
mild obesity (Body Mass Index 32). The man was calm and cooperative 
during his ED visit. His vital signs were: ABP 160/100 mmHg, SpO2 97% 
while breathing room air (PaO2/FIO2=303 mmHg), HR 75/min, and 
body temperature 36.7 ◦C. His white blood cell count was 3849/mm3, 
platelets were 62,000/mm3 (abnormal), and lymphocytes were 2140/ 
mm3. C-reactive protein was 1.48 mg/L, procalcitonin (PCT) was 0.04 
ng/ml, pro-adrenomedullin (pro-ADM) was 0.69 nMol/L, and IL-6 was 
27.0 pg/mL (abnormal). A real-time PCR nasal swab tested positive for 
SARS-COV2. 
The patient was then admitted to the infectious diseases ward (day 0) 
where he was treated with dexamethasone intravenously 6 mg per day. 
Given his worsening clinical situation, which necessitated increasing 
levels of oxygen provided by non-invasive ventilation using a full face 
mask, he was finally admitted to the ICU (day 8). In the ICU, the patient 
required immediate endotracheal intubation and invasive mechanical 
ventilation due to worsening dyspnoea associated with a PaO2/FIO2 of 
135 mmHg. On his second day in the ICU (day 10), the patient’s IL-6 
levels reached 223.0 pg/mL (abnormal), thus the decision to admin-
ister tocilizumab that same day was taken (the patient was also being 
treated with entecavir for HBV-related cirrhosis). 
Following tocilizumab administration, pre-emptive ceftobiprole 
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treatment was started, 500 mg intravenously every 8 hours according to 
our internal protocol (day 10 until day 19). On day 15, the patient un-
derwent an early percutaneous tracheostomy, as per our routine practice 
in COVID-19 patients, in order to facilitate easier weaning from me-
chanical ventilation. 
On day 23, acyclovir (10 mg/kg BW) was administered intravenously 
every 8 hours to treat Herpes reactivation (HSV1-DNA detected in blood: 
5197 copies/mL, abnormal). The same day, liposomal amphotericin B (3 
mg/kg BW that was stopped after 30 days of therapy) was also given 
despite the absence of microbiological findings due to the suspicion of 
CAPA as suggested by the patient’s high serum levels of β–D glucan 
(86.9 pg/ml, abnormal). 
Aspergillus fumigatus was finally isolated from the bronchial aspirate 
on day 37, 22 days after tocilizumab administration and 12 days after 
the first positive result for serum β–D glucan. 
Galactomannan levels in serum and alveolar fluid were tested on day 
17, 20, 26 and 32. In the same days bronchoalveolar lavage fluid was 
also investigated through standard bacterial and fungal cultures and 
multiplex PCR filmarray. All these tests resulted negative for Aspergillus. 
Repeated CT scans of the thorax showed the development over time 
of a cavity in the lung parenchyma, supporting our suspicion of pul-
monary Aspergillus infection (see Figs. 1–3). 
On day 43, the patient was discharged from the ICU to the Pneu-
mology Unit with spontaneous breathing through the tracheostomy, 
which was removed on day 58. He went to rehabilitation unit in good 
condition after 68 days of hospitalization. 
3. Discussion 
The COVID-19 pandemic raises important questions regarding the 
treatment of coronaviruses. To the best of our knowledge, no single drug 
has been demonstrated to be effective in critically ill patients, and more 
evidence is required [6,7]. Many drugs and treatments (e.g. hydroxy-
chloroquine, lopinavir/ritonavir, darunavir/cobicistat, etc.) have been 
proposed for the treatment of critically ill COVID-19 patients. One goal 
of these treatments is to reduce viral spread and replication. Another is 
to limit hyperinflammation and the triggering of a systemic response 
during the later phase of an infection which could lead to multiorgan 
dysfunction [8]. 
Steroids constitute the cornerstone treatment for COVID-19. The aim 
of steroid treatment is to modulate the inflammatory response, being 
recognized as a standard of care in the latest WHO guidelines [9]. Other 
drugs have also been proposed and tested for their capacity to limit the 
hyperinflammation that characterizes the later stages of COVID-19. 
These include inhibitors of the IL-1β and IL-6 receptor, of which ana-
kinra and tocilizumab are the most commonly used. It is worth noting 
here that IL-6 also promotes viral and bacterial clearance. However, 
excessive inflammation could increase vascular permeability, inducing 
acute respiratory distress syndrome (ARDS), cardiac arrhythmia and 
other negative consequences [10]. 
From a theoretical perspective, tocilizumab therapy is currently 
considered the most appropriate. Its overall goal is to prevent multi-
organ dysfunction caused by a cytokine storm. However, the associated 
consequences of immunosuppression must also be taken into account. 
Warnings about the increased risk of bacterial and fungal infections 
following immunosuppressant therapy have become more numerous 
over the last year [11]. Lymphopenia is present in a high percentage of 
COVID-19 patients. The additional use of steroids and other immuno-
suppressive drugs thus increases the risk for fungal infections, especially 
Aspergillus sp. In the case described, HBV-related cirrhosis was an 
additional risk factor for fungal infection. Indeed, evidence suggests 
Fig. 1. CT scan of the thorax at hospital admission (day 0) demonstrates diffuse 
subpleural ground-glass opacity. 
Fig. 2. CT scan of the thorax taken on day 14 demonstrates the appearance of 
consolidation in the upper left pulmonary lobe (blue arrow), extended ground- 
glass opacity and the crazy-paving pattern associated with posterior lung 
consolidation. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the Web version of this article.) 
Fig. 3. CT scan (day 28) demonstrating a large septated cavity in the lung 
parenchyma suspected to be an Aspergillus lesion (blue arrow). (For interpre-
tation of the references to colour in this figure legend, the reader is referred to 
the Web version of this article.) 
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there to be more secondary infections in COVID-19 patients treated with 
tocilizumab than in those not receiving the drug [12]. Moreover, it is 
difficult to confirm suspected infections using standard laboratory tests 
for infection, such as C-reactive protein or procalcitonin. These markers 
rapidly decrease after tocilizumab administration, with very low values 
persisting for many days. As a consequence, doctors are unlikely to 
suspect an infection. 
Some authors recommend empirical antibiotic prophylaxis, 
including antifungal drugs. Indeed, the difficulty and time involved in 
isolating Aspergillus from bronchoalveolar lavage fluid further support 
the adoption of an empirical antifungal approach to COVID-19 therapy 
in critically ill patients [13]. In fact, in the case herein described, 
following our initial suspicion of CAPA due to the significant increase in 
β–D glucan levels (on day 23), the first microbiological specimen testing 
positive for Aspergillus was not obtained until 12 days later. 
Diagnosis of invasive pulmonary aspergillosis (IPA) in the ICU re-
mains challenging. For this reason, the European Organization for 
Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) 
criteria have been supplemented with a specific algorithm in critically ill 
patients [14]. Although biomarkers of Aspergillus infection, such as 
serum galactomannan or β–D glucan, are generally deemed to be 
unsensitive, testing for their presence in serum and bronchoalveolar 
lavage fluid was recently added to the EORTC/MSG criteria to aid the 
identification of IPA in influenza patients admitted to ICU. In our case, in 
addition to the patient’s risk factors for IPA, the sudden increase in β–D 
glucan levels was enough for us to deem therapy with a broad spectrum 
antifungal necessary. Curiously, although the patient tested positive for 
β–D glucan, he remained negative for galactomannan. 
In the present case, tocilizumab may have favoured CAPA, although 
this remains to be proven. 
Many questions remain unanswered regarding the role of tocilizu-
mab therapy in COVID-19. Physicians generally prescribe it believing 
that they are damping down the fire … however, in some cases, it might 
be better likened to adding gasoline and not water! 
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